Viridian Therapeutics, Inc.

The momentum for this stock is not very good. Viridian Therapeutics, Inc. is not a good value stock. Viridian Therapeutics, Inc. is not a good growth stock. Tradey thinks it is not wise to invest in Viridian Therapeutics, Inc. .

News

Viridian Therapeutics (NASDAQ:VRDN) PT Raised to $38.00

Zolmax Viridian Therapeutics (NASDAQ:VRDN - Free Report) had its price objective raised by Needham Company LLC from $30.00 to $38.00 in a research note released on Wednesday morning, Marketbeat...\n more…

Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $38.00 at Needham & Company LLC

Ticker Report Viridian Therapeutics (NASDAQ:VRDN - Free Report) had its price target lifted by Needham Company LLC from $30.00 to $38.00 in a research note released on Wednesday, Marketbeat reports. Needham...\n more…

Viridian Therapeutics slides on pricing $225M securities offering

Seeking Alpha - Healthcare Viridian Therapeutics slides on pricing $225M securities offering...\n more…

Viridian Therapeutics (NASDAQ:VRDN) Sees Large Volume Increase Following Analyst Upgrade

Ticker Report Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) saw unusually-high trading volume on Wednesday after Needham Company LLC raised their price target on the stock from...\n more…

Viridian Therapeutics (NASDAQ:VRDN) Rating Reiterated by HC Wainwright

Zolmax Viridian Therapeutics (NASDAQ:VRDN - Get Free Report)s stock had its "buy" rating reissued by research analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They...\n more…

Viridian Therapeutics 10.67M share Secondary priced at $18.75

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…